S&P 500   3,236.92 (-2.37%)
DOW   26,763.13 (-1.92%)
QQQ   263.74 (-3.21%)
AAPL   107.02 (-4.28%)
MSFT   200.33 (-3.42%)
FB   248.85 (-2.32%)
GOOGL   1,406.90 (-3.63%)
AMZN   3,000.49 (-4.11%)
NVDA   484.65 (-4.13%)
TSLA   378.77 (-10.72%)
BABA   273.00 (-0.83%)
CGC   14.75 (-8.04%)
GE   6.11 (-2.24%)
MU   49.84 (+0.28%)
AMD   74.58 (-4.02%)
T   27.86 (-2.28%)
F   6.63 (-2.21%)
ACB   5.18 (-29.23%)
GILD   63.04 (-0.57%)
NFLX   470.23 (-4.26%)
DIS   123.34 (-3.04%)
BAC   23.29 (-2.72%)
BA   151.18 (-3.58%)
S&P 500   3,236.92 (-2.37%)
DOW   26,763.13 (-1.92%)
QQQ   263.74 (-3.21%)
AAPL   107.02 (-4.28%)
MSFT   200.33 (-3.42%)
FB   248.85 (-2.32%)
GOOGL   1,406.90 (-3.63%)
AMZN   3,000.49 (-4.11%)
NVDA   484.65 (-4.13%)
TSLA   378.77 (-10.72%)
BABA   273.00 (-0.83%)
CGC   14.75 (-8.04%)
GE   6.11 (-2.24%)
MU   49.84 (+0.28%)
AMD   74.58 (-4.02%)
T   27.86 (-2.28%)
F   6.63 (-2.21%)
ACB   5.18 (-29.23%)
GILD   63.04 (-0.57%)
NFLX   470.23 (-4.26%)
DIS   123.34 (-3.04%)
BAC   23.29 (-2.72%)
BA   151.18 (-3.58%)
S&P 500   3,236.92 (-2.37%)
DOW   26,763.13 (-1.92%)
QQQ   263.74 (-3.21%)
AAPL   107.02 (-4.28%)
MSFT   200.33 (-3.42%)
FB   248.85 (-2.32%)
GOOGL   1,406.90 (-3.63%)
AMZN   3,000.49 (-4.11%)
NVDA   484.65 (-4.13%)
TSLA   378.77 (-10.72%)
BABA   273.00 (-0.83%)
CGC   14.75 (-8.04%)
GE   6.11 (-2.24%)
MU   49.84 (+0.28%)
AMD   74.58 (-4.02%)
T   27.86 (-2.28%)
F   6.63 (-2.21%)
ACB   5.18 (-29.23%)
GILD   63.04 (-0.57%)
NFLX   470.23 (-4.26%)
DIS   123.34 (-3.04%)
BAC   23.29 (-2.72%)
BA   151.18 (-3.58%)
S&P 500   3,236.92 (-2.37%)
DOW   26,763.13 (-1.92%)
QQQ   263.74 (-3.21%)
AAPL   107.02 (-4.28%)
MSFT   200.33 (-3.42%)
FB   248.85 (-2.32%)
GOOGL   1,406.90 (-3.63%)
AMZN   3,000.49 (-4.11%)
NVDA   484.65 (-4.13%)
TSLA   378.77 (-10.72%)
BABA   273.00 (-0.83%)
CGC   14.75 (-8.04%)
GE   6.11 (-2.24%)
MU   49.84 (+0.28%)
AMD   74.58 (-4.02%)
T   27.86 (-2.28%)
F   6.63 (-2.21%)
ACB   5.18 (-29.23%)
GILD   63.04 (-0.57%)
NFLX   470.23 (-4.26%)
DIS   123.34 (-3.04%)
BAC   23.29 (-2.72%)
BA   151.18 (-3.58%)
Log in
LON:VRP

Verona Pharma Share Forecast, Price & News

GBX 62.50
0.00 (0.00 %)
(As of 09/22/2020 12:00 AM ET)
Add
Compare
Today's Range
61.75
Now: GBX 62.50
64.50
50-Day Range
62.50
MA: GBX 72.12
82.50
52-Week Range
0.66
Now: GBX 62.50
115
Volume118,195 shs
Average Volume154,340 shs
Market Capitalization£259.09 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.
Read More
Verona Pharma logo


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-20-32834200

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash FlowGBX 15.40 per share
Book ValueGBX 18 per share

Profitability

Miscellaneous

Employees22
Market Cap£259.09 million
Next Earnings DateN/A
OptionableOptionable
GBX 62.50
0.00 (0.00 %)
(As of 09/22/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VRP News and Ratings via Email

Sign-up to receive the latest news and ratings for VRP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Verona Pharma (LON:VRP) Frequently Asked Questions

How has Verona Pharma's stock price been impacted by COVID-19?

Verona Pharma's stock was trading at GBX 49 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, VRP stock has increased by 27.6% and is now trading at GBX 62.50.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Verona Pharma?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verona Pharma in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Verona Pharma
.

How were Verona Pharma's earnings last quarter?

Verona Pharma Plc (LON:VRP) announced its quarterly earnings results on Thursday, February, 27th. The company reported ($30.30) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($30.80) by $0.50.
View Verona Pharma's earnings history
.

Who are some of Verona Pharma's key competitors?

What other stocks do shareholders of Verona Pharma own?

Who are Verona Pharma's key executives?

Verona Pharma's management team includes the following people:
  • Dr. Jan-Anders Karlsson, CEO & Exec. Director (Age 64)
  • Mr. Piers John Morgan, Chief Financial Officer (Age 53)
  • Ms. Claire Louise Poll L.C.S.W., B.A., B Juris, LLB, ASIA, Gen. Counsel (Age 52)
  • Ms. Victoria Stewart, Director of Communications
  • Dr. Peter Spargo, Sr. VP of Chemistry Manufacturing & Controls (Age 57)

What is Verona Pharma's stock symbol?

Verona Pharma trades on the London Stock Exchange (LON) under the ticker symbol "VRP."

How do I buy shares of Verona Pharma?

Shares of VRP and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Verona Pharma's stock price today?

One share of VRP stock can currently be purchased for approximately GBX 62.50.

How big of a company is Verona Pharma?

Verona Pharma has a market capitalization of £259.09 million. Verona Pharma employs 22 workers across the globe.

What is Verona Pharma's official website?

The official website for Verona Pharma is www.veronapharma.com.

How can I contact Verona Pharma?

Verona Pharma's mailing address is 3 More London Riverside, LONDON, SE1 2RE, United Kingdom. The company can be reached via phone at +44-20-32834200.

This page was last updated on 9/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.